.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,313,951

« Back to Dashboard

Claims for Patent: 4,313,951

Title: 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor
Abstract:1-R.sub.1 -3-[amino, cyano, carbamyl, halo, lower-alkylamino, di-(lower-alkyl)amino or lower-acylamino]-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones or pharmaceutically-acceptable acid-addition or cationic salts thereof are useful as cardiotonic agents, where R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl. 1-R.sub.1 -3-amino-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones are prepared by hydrolyzing the corresponding 3-cyano compounds to produce the corresponding 3-carbamyl compounds and reacting the latter with a reagent capable of converting carbamyl to amino. The 1-R.sub.1 -3-cyano-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones are prepared by reacting (pyridinylmethyl) lower-alkyl ketones with dimethylformamide di-(lower-alkyl) acetal to produce 1-(pyridinyl)-2-(dimethylamino)ethenyl lower-alkyl ketone and reacting said ketones with N-R.sub.1 -.alpha.-cyanoacetamide to produce the 1-R.sub.1 -3-cyano-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones. Also shown are the conversions: of the 3-cyano compounds to the 3-H compounds; of the 3-H compounds to the 3-halo compounds; of the 3-halo compounds to the 3-[mono-(lower-alkyl)- or di-(lower-alkyl)-amino]compounds; and, of the 3-amino compounds to the 3-lower-acylamino or 3-[mono-(lower-alkyl)- or di-(lower-alkyl)amino] compounds.
Inventor(s): Lesher; George Y. (Schodack, NY), Philion; Richard E. (Schodack, NY)
Assignee: Sterling Drug Inc. (New York, NY)
Application Number:06/198,461
Patent Claims: 1. A 1-R.sub.1 -3-Q-5-PY-6-R-2(1H)-pyridinone having the formula ##STR3## where Q is amino, cyano, carbamyl, halo, lower-alkylamino, di-(lower-alkyl)amino or lower-acylamino, R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl and PY is 4-, 3- or 2-pyridinyl or 4-, 3- or 2-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically-acceptable acid-addition or cationic salt thereof.

2. A compound according to claim 1 where Q is amino.

3. A compound according to claim 1 where Q is cyano.

4. A compound according to claim 1 where Q is carbamyl.

5. A compound according to claim 1 where Q is halo.

6. A compound according to claim 1 where Q is lower-alkylamino.

7. A compound according to claim 1 where Q is di-(lower-alkyl)amino.

8. A compound according to claim 1 where Q is lower-acylamino.

9. 3-Amino-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically-acceptable acid-addition salt thereof.

10. 3-Amino-6-ethyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically-acceptable acid-addition salt thereof.

11. 3-Amino-6-n-propyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically-acceptable acid-addition salt thereof.

12. 1,2-Dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile or pharmaceutically-acceptable acid-addition salt thereof.

13. 6-Methyl-3-methylamino-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically-acceptable acid-addition salt thereof.

14. 3-Bromo-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically-acceptable acid-addition salt thereof.

15. 6-Ethyl-1,2-dihydro-2-oxo-5-(4-pyridinyl)nicotinonitrile according to claim 3.

16. 1,2-Dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinamide according to claim 4.

17. 6-Ethyl-1,2-dihydro-2-oxo-5-(4-pyridinyl)nicotinamide according to claim 4.

18. 3-Ethylamino-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone according to claim 6.

19. 3-Dimethylamino-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone according to claim 7.

20. A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 1-R.sub.1 -3-Q-5-PY-6-R-2(1H)pyridinone having the formula ##STR4## where Q is amino, cyano, carbamyl, halo, lower-alkylamino, di-(lower-alkyl)amino or lower-acylamino, R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl and PY is 4-, 3- or 2-pyridinyl or 4-, 3- or 2-pyridinyl having one or two lower-alkyl substituents, or pharmaceutically-acceptable acid-addition or cationic salt thereof.

21. A composition according to claim 20 where the active component is 3-amino-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically-acceptable acid-addition salt thereof.

22. A composition according to claim 20 where the active component is 1,2-dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile or pharmaceutically-acceptable acid-addition salt thereof.

23. A composition according to claim 20 where the active component is 3-amino-6-ethyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically-acceptable acid-addition salt thereof.

24. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 1-R.sub.1 -3-Q-5-PY-6-R-2(1H)-pyridinone having the formula ##STR5## where Q is amino, cyano, carbamyl, halo, lower-alkylamino, di-(lower-alkyl)amino or lower-acylamino, R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl and PY is 4-, 3- or 2-pyridinyl or 4-, 3- or 2-pyridinyl having one or two lower-alkyl substitutents, or pharmaceutically-acceptable acid-addition or cationic salt thereof.

25. The method according to claim 24 where Q is amino, R is methyl or ethyl, and PY is 4-pyridinyl.

26. The method according to claim 24 where Q is cyano, R is methyl or ethyl, and PY is 4-pyridinyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc